GoAI
Get started
Immunome, Inc. logo

Immunome, Inc.

IMNM

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$28.52

+$0.44 · +1.57%

Aug 21, 4:00 PM ET

IMNM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

15

Overpriced

Momentum

59

Neutral

Sentiment

75

Bullish

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Clay Siegall
Listed since
Oct 2, 2020
Employees
247

Market position

Day range

Current $28.52

52-week range

Current $28.52

Open
$28.31
Previous close
$28.08
Volume
848.79K
0.68× average
Average volume
1.25M
Average daily volume
Market cap
2.73B USD
Beta
2.12
Market reference 1
50-day average
$23.0751
+23.60% above average
200-day average
$21.7527
+31.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.23B USD
P/E (TTM)
-11.23×
P/B (TTM)
6.15×
P/S (TTM)
0×
EV / EBITDA
-5.86×
Earnings yield
-11.32%
Free cash flow yield
-10.69%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-33.48%
Return on assets
-31.09%
Return on invested capital
-33.55%

Financial health

Debt / equity
0.01×
Current ratio
14.69×
Altman Z-score
38.06
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends448%-945%-2338%-3731%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 57.43%Operating margin, FY2023: -781.35%Operating margin, FY2024: -3382.37%Operating margin, FY2025: -3084.76%Net margin, FY2023: -761.92%Net margin, FY2024: -3240.38%Net margin, FY2025: -3059.99%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 57.43%. Operating margin FY2023 -781.35%. Operating margin FY2024 -3382.37%. Operating margin FY2025 -3084.76%. Net margin FY2023 -761.92%. Net margin FY2024 -3240.38%. Net margin FY2025 -3059.99%.

Income trends

Revenue

6.94M USD-23.23%

Operating income

−214.11M USD+29.98%

Net income

−212.39M USD+27.50%
Income trends across reported periods46M USD−81.93M USD−209.85M USD−337.78M USDRevenue, FY2023: 14.02M USDRevenue, FY2024: 9.04M USDRevenue, FY2025: 6.94M USDOperating income, FY2021: −25.2M USDOperating income, FY2022: −36.9M USDOperating income, FY2023: −109.53M USDOperating income, FY2024: −305.8M USDOperating income, FY2025: −214.11M USDNet income, FY2021: −24.71M USDNet income, FY2022: −36.9M USDNet income, FY2023: −106.81M USDNet income, FY2024: −292.96M USDNet income, FY2025: −212.39M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 14.02M USD. Revenue FY2024 9.04M USD. Revenue FY2025 6.94M USD. Operating income FY2021 −25.2M USD. Operating income FY2022 −36.9M USD. Operating income FY2023 −109.53M USD. Operating income FY2024 −305.8M USD. Operating income FY2025 −214.11M USD. Net income FY2021 −24.71M USD. Net income FY2022 −36.9M USD. Net income FY2023 −106.81M USD. Net income FY2024 −292.96M USD. Net income FY2025 −212.39M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.94M USD9.04M USD14.02M USD——
Cost of goods sold2.96M USD————
Gross profit3.99M USD9.04M USD14.02M USD——
Research and development174.33M USD129.54M USD23.09M USD23.27M USD14.11M USD
Selling, general, and administrative43.77M USD32.96M USD19.66M USD13.63M USD11.09M USD
Operating expenses218.1M USD314.84M USD123.55M USD36.9M USD25.2M USD
Interest income11.72M USD12.84M USD2.72M USD5K USD10K USD
Interest expense———5K USD10K USD
Depreciation and amortization2.96M USD2.1M USD728K USD631K USD755K USD
Operating income−214.11M USD−305.8M USD−109.53M USD−36.9M USD−25.2M USD
Net income−212.39M USD−292.96M USD−106.81M USD−36.9M USD−24.71M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-161.13%
11 comparable reports
Latest EPS result
-0.65
Estimate -0.51 · Miss by 26.51%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.44-0.59-0.73-0.88Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -0.84, estimate -0.68, surprise -23.53%, Miss. Q2 2025, reported May 12, 2025: actual -0.52, estimate -0.66, surprise +21.21%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.5, estimate -0.52, surprise +3.85%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.65, estimate -0.57, surprise -14.04%, Miss. Q1 2026, reported Mar 3, 2026: actual -0.75, estimate -0.59, surprise -27.08%, Miss. Q2 2026, reported May 12, 2026: actual -0.48, estimate -0.6, surprise +20.00%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.65, estimate -0.514, surprise -26.51%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.64, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.32M2.93M1.54M141.67KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual 2.74M USD, estimate 3.15M USD, surprise -12.99%, Miss. Q2 2025, reported May 12, 2025: actual 2.93M USD, estimate 457.14K USD, surprise +540.07%, Beat. Q3 2025, reported Aug 6, 2025: actual 4.02M USD, estimate 833.33K USD, surprise +381.80%, Beat. Q4 2025, reported Nov 6, 2025: actual —, estimate 850K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 3, 2026: actual —, estimate 876.03K USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 222.22K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 11, 2026: actual —, estimate 166.67K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 181.82K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

13 ratings
Strong buy00%
Buy13100%
Hold00%
Sell00%
Strong sell00%

IMNM news

marketbeat.com

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing

argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated…

Read source
globenewswire.com

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study;…

Read source
seekingalpha.com

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon

I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified, with IM-1021 [ROR1…

Read source
businesswire.com

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter…

Read source
businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3,…

Read source
defenseworld.net

Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM

Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).…

Read source

IMNM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IMNM

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
88.19M
Weight
0.77%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
75.9M
Weight
0.09%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
73.76M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
27.9M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
27.51M
Weight
0.18%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
14.32M
Weight
0.06%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
13.46M
Weight
0.08%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Tema Oncology ETF logoTema Oncology ETFCANC
Market value
6.53M
Weight
3.03%
AUM
215.38M USD
Expense ratio
0.99%
Price / 1D
$44.5939+1.28%

Continue in GoAI

Research IMNM

research.disclaimer